The slowness of AD dementia progression may magnify the potential impact of DMTs on quality of life and health care costs. For example, a modest slowing of disease progression as seen in the lecanemab trial could translate into an additional year of independent living for those starting with CDR‐SB = 1, or 9 months of independent living for those starting with CDR‐SB = 2. Delaying a move to an assisted living facility, with an average yearly cost of $56,068, 17 could result in a significant savings to patients and families.
